Evidence map›Paper›PMID 29573550›Full record

ArticleCytometry. Part A : the journal of the International Society for Analytical Cytology2018

Relative quantification of beta-adrenergic receptor in peripheral blood cells using flow cytometry.

Didem Saygin, Nicholas Wanner, Jonathan A Rose, Sathyamangla V Naga Prasad, W H Wilson Tang, Serpil Erzurum, Kewal Asosingh

Open access · bronzeAbstract read
In one paragraph

Article in Cytometry. Part A : the journal of the International Society for Analytical Cytology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.5field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 12 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Neurohormonal modulation in pulmonary arterial hypertension.The European respiratory journal · 2021
    Review
  6. Article
  7. β-blockers Reverse Agonist-Induced βInternational journal of molecular sciences · 2020
    Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Didem SayginDepartment of Pathobiology, Lerner Research Institute Cleveland Clinic, Cleveland, Ohio.
Nicholas WannerDepartment of Pathobiology, Lerner Research Institute Cleveland Clinic, Cleveland, Ohio.
Jonathan A RoseDepartment of Internal Medicine, Beth Israel Deaconess Medical Center Harvard Medical School, Boston, Massachusetts.
Sathyamangla V Naga PrasadDepartment of Molecular Cardiology, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio.
W H Wilson TangDepartment of Molecular Cardiology, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio.
Serpil ErzurumDepartment of Pathobiology, Lerner Research Institute Cleveland Clinic, Cleveland, Ohio.
Kewal AsosinghDepartment of Pathobiology, Lerner Research Institute Cleveland Clinic, Cleveland, Ohio.
Cleveland Clinic Lerner College of Medicine · USBeth Israel Deaconess Medical Center · USCleveland Clinic · US

Funding

Clinical and Translational Science Collaborative of ClevelandUL1TR000439 · NCATS · CASE WESTERN RESERVE UNIVERSITY · PI KONSTAN, MICHAEL W. · 2012 to 2016
$50.0M
Pulmonary Vascular Disease Phenomics Program (PVDOMICS) Data Coordinating CenterU01HL125177 · NHLBI · CLEVELAND CLINIC LERNER COM-CWRU · PI BECK, GERALD J, ERZURUM, SERPIL C. · 2014 to 2020
$20.0M
NITRIC OXIDE PRODUCTION AND REACTIONS IN THE LUNGR01HL060917 · NHLBI · CLEVELAND CLINIC LERNER COM-CWRU · PI Serpil C. Erzurum · 1999 to 2026
$6.3M
Nitric Oxide in Pulmonary HypertensionR37HL060917 · NHLBI · CLEVELAND CLINIC LERNER COM-CWRU · PI ERZURUM, SERPIL C. · 2009 to 2018
$3.9M
Pulmonary Vascular-Right Ventricular Axis Research ProgramR01HL115008 · NHLBI · CLEVELAND CLINIC LERNER COM-CWRU · PI ERZURUM, SERPIL C., PRASAD, SATHYAMANGLA V · 2012 to 2016
$3.1M
NCATS NIH HHS UL1 TR000439NHLBI NIH HHS R01 HL060917NHLBI NIH HHS R01 HL115008NHLBI NIH HHS R37 HL060917NHLBI NIH HHS U01 HL125177
6 · The paper itself

Abstract

Beta-adrenergic receptors (β-ARs) play a critical role in many diseases. Quantification of β-AR density may have clinical implications in terms of assessing disease severity and identifying patients who could potentially benefit from beta-blocker therapy. Classical methods for β-AR quantification are based on labor-intensive and time-consuming radioligand binding assays. Here, we report optimization of a flow cytometry-based method utilizing a biotinylated β-AR ligand alprenolol as a probe and use of this method to quantify relative receptor expression in healthy controls (HC). Quantum™ MESF beads were used for quantification in absolute fluorescence units. The probe was chemically modified by adding a spacer moiety between biotin and alprenolol to stabilize receptor binding, thus preventing binding decay. Testing of three different standard cell fixation and permeabilization methods (formaldehyde fixation and saponin, Tween-20, or Triton-X 100 permeabilization) showed that the formaldehyde/Triton-X 100 method yielded the best results. β-AR expression was significantly higher in granulocytes compared to mononuclear cells. These data show that flow cytometric quantification of relative β-AR expression in circulating leukocytes is a suitable technology for large-scale clinical application. © 2018 International Society for Advancement of Cytometry.

Indexed as

LeukocytesFlow CytometryHumansReceptors, Adrenergic, betaTissue FixationReceptors, Adrenergic, betabeta-adrenergic receptor peripheral blood cellsflow cytometryquantification

Identifiers

PMID29573550
PMCPMC7263462
OpenAlexW2801129023

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.